Encephalomyelitis - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Encephalomyelitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Encephalomyelitis - Pipeline Review, H1 2015', provides an overview of the Encephalomyelitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Encephalomyelitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Encephalomyelitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Encephalomyelitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Encephalomyelitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of table 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Encephalomyelitis Overview 6
Therapeutics Development 7
Pipeline Products for Encephalomyelitis - Overview 7
Pipeline Products for Encephalomyelitis - Comparative Analysis 8
Encephalomyelitis - Therapeutics under Development by Companies 9
Encephalomyelitis - Therapeutics under Investigation by Universities/Institutes 10
Encephalomyelitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Encephalomyelitis - Products under Development by Companies 13
Encephalomyelitis - Products under Investigation by Universities/Institutes 14
Encephalomyelitis - Companies Involved in Therapeutics Development 15
Effimune SAS 15
Endocyte, Inc. 16
Immune Technologies and Medicine 17
InteKrin Therapeutics, Inc. 18
Io Therapeutics, Inc. 19
Merck & Co., Inc. 20
Momenta Pharmaceuticals, Inc. 21
Encephalomyelitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 30
Anatabine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EC-1496 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
FR-104 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
INT-131 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IRX-5183 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PETIR-001 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PSA-20 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SCH-546738 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Antagonize VLA-4 for Arthritis, Asthma and Encephalomyelitis - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
thymulin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Encephalomyelitis - Recent Pipeline Updates 44
Encephalomyelitis - Dormant Projects 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for Encephalomyelitis, H1 2015 7
Number of Products under Development for Encephalomyelitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Encephalomyelitis - Pipeline by Effimune SAS, H1 2015 15
Encephalomyelitis - Pipeline by Endocyte, Inc., H1 2015 16
Encephalomyelitis - Pipeline by Immune Technologies and Medicine, H1 2015 17
Encephalomyelitis - Pipeline by InteKrin Therapeutics, Inc., H1 2015 18
Encephalomyelitis - Pipeline by Io Therapeutics, Inc., H1 2015 19
Encephalomyelitis - Pipeline by Merck & Co., Inc., H1 2015 20
Encephalomyelitis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Encephalomyelitis Therapeutics - Recent Pipeline Updates, H1 2015 44
Encephalomyelitis - Dormant Projects, H1 2015 46